对比增强CT与PET/CT对晚期卵巢癌分期的诊断准确性:比较性系统评价与Meta分析
该系统评价与Meta分析纳入15项研究共918例患者,比较对比增强CT与PET/CT检测卵巢癌腹部转移的诊断准确性。基于患者分析的敏感度对比增强CT为82%(95%CI 67-91%)、PET/CT为87%(95%CI 75-94%),两者无显著差异(p=0.29);特异度对比增强CT为72%(95%CI 59-82%)、PET/CT为90%(95%CI 82-95%),PET/CT显著高于CT(p<0.01)。
要点
- 基于患者分析,对比增强CT与PET/CT检测卵巢癌腹部转移的敏感度无显著差异(p=0.29)。
- 基于患者分析,PET/CT特异度90%显著高于对比增强CT的72%(p<0.01)。
- 对比增强CT敏感度82%(95%CI 67-91%),PET/CT敏感度87%(95%CI 75-94%)。
核心结论
- 对比增强CT的敏感度不劣于PET/CT,但PET/CT仍可能作为CT的替代和/或补充用于卵巢癌患者诊断性腹腔镜前和/或替代诊断性腹腔镜;现有指南的未来修订应考虑这些结果以进一步完善个体化治疗前诊断路径。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、EMBASE、Scopus、Cochrane图书馆及灰色文献自建库至2022年10月,纳入15项研究共918例患者(平均年龄范围51至65岁),其中12项评价对比增强CT(6项基于患者分析、6项基于区域分析),11项评价PET/CT(7项基于患者分析、4项基于区域分析);参考标准为手术/组织病理学±临床随访;主要Meta分析采用双变量混合效应回归模型,偏倚风险采用QUADAS-2评价。
诊断标准与关键数值
- 基于患者分析,对比增强CT检测晚期卵巢癌的敏感度为82%(95%CI 67-91%),特异度为72%(95%CI 59-82%)。
- 基于患者分析,PET/CT检测晚期卵巢癌的敏感度为87%(95%CI 75-94%),特异度为90%(95%CI 82-95%)。
- 两种方法敏感度无显著差异(p=0.29),PET/CT特异度显著高于CT(p<0.01)。
局限性
- 由于基于患者分析的研究数量有限,任何单一类别中推测的变异性均无法评估。
- 所有报告研究除一项外均采用共识判读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Accurate staging of ovarian cancer is critical to guide optimal management pathways. North American guidelines recommend contrast-enhanced CT as the primary work-up for staging ovarian cancer. This meta-analysis aims to compare the diagnostic accuracy of contrast-enhanced CT alone to PET/CT for detecting abdominal metastases in patients with a new or suspected diagnosis of ovarian cancer.
MATERIALS AND METHODS: A systematic review of MEDLINE, EMBASE, Scopus, the Cochrane Library, and the gray literature from inception to October 2022 was performed. Studies with a minimum of 5 patients evaluating the diagnostic accuracy of contrast-enhanced CT and/or PET/CT for detecting stage 3 ovarian cancer as defined by a surgical/histopathological reference standard ± clinical follow-up were included. Study, clinical, imaging, and accuracy data for eligible studies were independently acquired by two reviewers. Primary meta-analysis was performed in studies reporting accuracy on a per-patient basis using a bivariate mixed-effects regression model. Risk of bias was evaluated using QUADAS-2.
RESULTS: From 3701 citations, 15 studies (918 patients with mean age ranging from 51 to 65 years) were included in the systematic review. Twelve studies evaluated contrast-enhanced CT (6 using a per-patient assessment and 6 using a per-region assessment) and 11 studies evaluated PET/CT (7 using a per-patient assessment and 4 using a per-region assessment). All but one reporting study used consensus reading. Respective sensitivity and specificity values on a per-patient basis were 82% (67-91%, 95% CI) and 72% (59-82%) for contrast-enhanced CT and 87% (75-94%) and 90% (82-95%) for PET/CT. There was no significant difference in sensitivities between modalities (p = 0.29), but PET/CT was significantly more specific than CT (p < 0.01). Presumed variability could not be assessed in any single category due to limited studies using per-patient assessment. Studies were almost entirely low risk for bias and applicability concerns using QUADAS-2.
CONCLUSION: Contrast-enhanced CT demonstrates non-inferior sensitivity compared to PET/CT, although PET/CT may still serve as an alternative and/or supplement to CT alone prior to and/or in lieu of diagnostic laparoscopy in patients with ovarian cancer. Future revisions to existing guidelines should consider these results to further refine the individualized pretherapeutic diagnostic pathway.
引用
- Wilson MP, Sorour S, Bao B, et al. Diagnostic accuracy of contrast-enhanced CT versus PET/CT for advanced ovarian cancer staging: a comparative systematic review and meta-analysis. Abdom Radiol (NY). 2024. PMID: 38523146. doi:10.1007/s00261-024-04195-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。